f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Hintermann Series H3 TAR Performance Study

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Ongoing
Application Number /
Requirement Number
P160036 / PAS002
Date Original Protocol Accepted 11/29/2019
Date Current Protocol Accepted 10/15/2021
Study Name Hintermann Series H3 TAR Performance Study
Device Name Hintermann Series H3 Total Ankle Replacement System
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives The purpose of this multi-center post-approval study is to meet the conditions of the PMA approval for the H3 TAR, to evaluate the trends in performance among implant sizes, and to assess the outcomes of the primary surgeon of the premarket study that supported PMA approval, compared to other surgeons that are less familiar with the device.
Design: Prospective, multicenter, single arm post approval study
Study Population Patients who have discussed options for management of a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis, or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis, etc.), and who have decided to undergo total ankle replacement, are candidates for this study.
Sample Size 232 Subjects/13 US clinical sites
Key Study Endpoints Safety:
Reoperation, revisions or removals of the H3 TAR device Incidence, occurrence, and types of serious device-related adverse events
Nature, onset, duration, severity, relationship to the device, and relationship to the operative procedure and outcome of any adverse event
Survivorship (absence of removal/revisions to include polyethylene revision)
AOFAS Scores
VAS Scores
Subject Satisfaction Surveys
PROMIS - Global Health
PROMIS – Emotional Distress-Anxiety
PROMIS – Emotional Distress-Depression
PROMIS – Pain Intensity
Implant migration
Any other findings
Explant analysis:
Any explanted devices / device components will be returned and handled for analysis as described in Attachment G: Explant and Revision Protocol
Follow-up Visits and Length of Follow-up 5 years post procedure
Interim or Final Data Summary
Actual Number of Patients Enrolled 66
Actual Number of Sites Enrolled 10

Hintermann Series H3 TAR Performance Study Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
1 year report 06/03/2020 06/03/2020 On Time
2 year report 06/03/2021 06/04/2021 Overdue/Received
3 year report 06/03/2022 06/06/2022 Overdue/Received
4 year report 06/03/2023 06/02/2023 On Time
amended report 05/23/2024 05/23/2024 On Time
5 year report 06/02/2024 06/03/2024 Overdue/Received
6 year report 06/02/2025    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources